CTRI/2023/07/054778Not yet recruitingUnknown
Prospective Global Platform to Evaluate & Enhance Cognitive and Functional Trajectories after Stroke - PROSPECT
Hamilton Health Sciences Population Health Research Institute0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •1. Ischemic stroke or ICH
- •2. 18 years or older
- •3. Within 16 weeks of the index event
- •4. ‘Probable stroke’ (high clinical suspicion of stroke based on acute focal neurological deficits in fitting with a neurovascular territory lasting for more than 24 hours, but without imaging confirmation of stroke) OR ‘definite stroke’ (brain imaging confirmed stroke [CT or MRI]).
Exclusion Criteria
- •1.Patients will be excluded if they are deemed by the investigators to be unlikely to adhere to study processes.
- •2.If they have a neurological condition (besides stroke) that is associated with cognitive or functional decline
- •3.An established diagnosis of pre-stroke dementia.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping temporarily pre-stroke antihypertensive therapy, in patients with acute strokeMedDRA version: 14.1Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10057613Term: Thromboembolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersAcute strokeMedDRA version: 14.1Level: LLTClassification code 10042244Term: StrokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10067816Term: Cardioembolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10027580Term: Middle cerebral artery strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10023027Term: Ischaemic stroke NOSSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10043647Term: Thrombotic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2004-003870-27-DKniversity of Nottingham, Research Innovation Services5,000
Completed
Not Applicable
Efficacy of nitric oxide in strokeAcute strokeCirculatory SystemStroke, not specified as haemorrhage or infarctionISRCTN99414122niversity of Nottingham (UK)3,500
Active, not recruiting
Phase 1
The Efficacy of Nitric Oxide in Stroke (ENOS) TrialStrokeEUCTR2004-003870-27-GRniversity of Nottingham, ResearchHead of research grants and contractsInnovation Services4,011
Active, not recruiting
Phase 1
A prospective, international, multi-centre, open-label, phase II study investigating the utility of [68Ga]Ga-PentixaFor PET imaging in response assessment (evaluation of the tumour response to the applied therapy) of primary (primary tumour in brain) and isolated secondary (secondary tumour in brain after relapse of a primary tumour not located in the brain) CNS lymphoma patientsCentral nervous system (CNS) lymphomaMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001711-85-NLPentixaPharm GmbH50
Withdrawn
Phase 2
A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphoma patientsCentral Nervous system lymphomaBrain lymphomaBrain tumor10025322NL-OMON51764PentixaPharm GmbH6